Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VH4011499 in Healthy Participants
NCT05393271Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VH4011499 in human immunodeficiency virus infection (HIV) (11 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants With Adverse Events (AEs) at Day 42, Number of Participants Discontinuing Treatment Due to AEs at Day 42 and 5 more. Started Oct 2022; status: completed.
02
Drugs
VH4011499
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05393271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393271.